Marina P Cristelli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3742482/publications.pdf

Version: 2024-02-01

687363 713466 63 635 13 21 citations h-index g-index papers 63 63 63 943 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Prolonged Delayed Graft Function Is Associated with Inferior Patient and Kidney Allograft Survivals. PLoS ONE, 2015, 10, e0144188.	2.5	61
2	High mortality among kidney transplant recipients diagnosed with coronavirus disease 2019: Results from the Brazilian multicenter cohort study. PLoS ONE, 2021, 16, e0254822.	2.5	51
3	Infectious complications as the leading cause of death after kidney transplantation: analysis of more than 10,000 transplants from a single center. Journal of Nephrology, 2017, 30, 601-606.	2.0	35
4	Wound Healing Complications in Kidney Transplant Recipients Receiving Everolimus. Transplantation, 2017, 101, 844-850.	1.0	30
5	The Full Spectrum of COVID-19 Development and Recovery Among Kidney Transplant Recipients. Transplantation, 2021, 105, 1433-1444.	1.0	30
6	Prospective Randomized Trial Investigating the Influence of Pharmaceutical Care on the Intra-Individual Variability of Tacrolimus Concentrations Early After Kidney Transplant: Erratum. Therapeutic Drug Monitoring, 2017, 39, 579-579.	2.0	24
7	Influence of epidemiology, immunosuppressive regimens, clinical presentation, and treatment on kidney transplant outcomes of patients diagnosed with tuberculosis: A retrospective cohort analysis. American Journal of Transplantation, 2019, 19, 1421-1431.	4.7	22
8	Efficacy of Convalescent Plasma to Treat Mild to Moderate COVID-19 in Kidney Transplant Patients: A Propensity Score Matching Analysis. Transplantation, 2022, 106, e92-e94.	1.0	21
9	Long-Term Follow-Up of De Novo Use of mTOR and Calcineurin Inhibitors After Kidney Transplantation. Therapeutic Drug Monitoring, 2016, 38, 22-31.	2.0	17
10	Development and validation of a simple web-based tool for early prediction of COVID-19-associated death in kidney transplant recipients. American Journal of Transplantation, 2022, 22, 610-625.	4.7	16
11	Donor-Specific Anti-Human Leukocyte Antigens Antibodies, Acute Rejection, Renal Function, and Histology in Kidney Transplant Recipients Receiving Tacrolimus and Everolimus. American Journal of Nephrology, 2017, 45, 497-508.	3.1	15
12	Prospective randomized study comparing everolimus and mycophenolate sodium in <i>de novo</i> kidney transplant recipients from expanded criteria deceased donor. Transplant International, 2019, 32, 1127-1143.	1.6	15
13	The Higher COVID-19 Fatality Rate Among Kidney Transplant Recipients Calls for Further Action. Transplantation, 2022, 106, 908-910.	1.0	15
14	Clinicopathological Characteristics and Effect of Late Acute Rejection on Renal Transplant Outcomes. Transplantation, 2014, 98, 885-892.	1.0	14
15	Targeted preemptive therapy according to perceived risk of CMV infection after kidney transplantation. Brazilian Journal of Infectious Diseases, 2016, 20, 576-584.	0.6	14
16	<scp>HLAâ€A</scp> homozygosis is associated with susceptibility to <scp>COVID</scp> â€19. Hla, 2021, 98, 122-131.	0.6	14
17	Prevalence and risk factors of mild chronic renal failure in HIV-infected patients: influence of female gender and antiretroviral therapy. Brazilian Journal of Infectious Diseases, 2018, 22, 193-201.	0.6	13
18	Early hospital readmission after kidney transplantation under a public health care system. Clinical Transplantation, 2019, 33, e13467.	1.6	13

#	Article	IF	CITATIONS
19	Inactivated Whole-virus Vaccine Triggers Low Response Against SARS-CoV-2 Infection Among Renal Transplant Patients: Prospective Phase 4 Study Results. Transplantation, 2022, 106, 853-861.	1.0	13
20	Clinical and pathological features of thrombotic microangiopathy influencing long-term kidney transplant outcomes. PLoS ONE, 2020, 15, e0227445.	2.5	12
21	The Influence of Antithymocyte Globulin Dose on the Incidence of CMV Infection in High-risk Kidney Transplant Recipients Without Pharmacological Prophylaxis. Transplantation, 2020, 104, 2139-2147.	1.0	12
22	The current burden of cytomegalovirus infection in kidney transplant recipients receiving no pharmacological prophylaxis. Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia, 2017, 39, 413-423.	0.9	12
23	The influence of clinical, environmental, and socioeconomic factors on five-year patient survival after kidney transplantation. Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia, 2018, 40, 151-161.	0.9	11
24	Safety profile comparing azathioprine and mycophenolate in kidney transplant recipients receiving tacrolimus and corticosteroids. Transplant Infectious Disease, 2013, 15, 369-378.	1.7	10
25	The influence of <scp>mTOR</scp> inhibitors on the incidence of <scp>CMV</scp> infection in highâ€risk donor positive–recipient negative (D+/Râ°') kidney transplant recipients. Transplant Infectious Disease, 2018, 20, e12907.	1.7	10
26	Incidence and risk factors associated with cytomegalovirus infection after the treatment of acute rejection during the first year in kidney transplant recipients receiving preemptive therapy. Transplant Infectious Disease, 2019, 21, e13106.	1.7	10
27	Kidney Transplantation in Patients With SARS-CoV-2 Infection: A Case Series Report. Transplantation, 2021, 105, e1-e3.	1.0	8
28	Expanding the use of expanded criteria donors in kidney transplantation. International Urology and Nephrology, 2014, 46, 1663-1671.	1.4	7
29	The effect of antiâ€thymocyte globulin and everolimus on the kinetics of cytomegalovirus viral load in seropositive kidney transplant recipients without prophylaxis. Transplant Infectious Disease, 2018, 20, e12919.	1.7	7
30	Kidney transplantation in the time of COVIDâ€19: Dilemmas, experiences, and perspectives. Transplant Infectious Disease, 2021, 23, e13600.	1.7	7
31	Renal transplantation in human immunodeficiency virusâ€infected recipients: a case–control study from the Brazilian experience. Transplant Infectious Disease, 2016, 18, 730-740.	1.7	6
32	Cost-Effectiveness Analysis of Everolimus versus Mycophenolate in Kidney Transplant Recipients Receiving No Pharmacological Prophylaxis for Cytomegalovirus Infection: A Short-Term Pharmacoeconomic Evaluation (12 Months). Value in Health Regional Issues, 2017, 14, 108-115.	1.2	6
33	Decreased incidence of acute rejection without increased incidence of cytomegalovirus (CMV) infection in kidney transplant recipients receiving rabbit antiâ€thymocyte globulin without CMV prophylaxis – a cohort singleâ€center study. Transplant International, 2021, 34, 339-352.	1.6	6
34	Comparison of 30-day case-fatality rate between dialysis and transplant Covid-19 patients: a propensity score matched cohort study. Journal of Nephrology, 2021, 35, 131.	2.0	6
35	Sexual acquisition of <scp>HIV</scp> infection after solid organ transplantation: Late presentation and potentially fatal complications. Transplant Infectious Disease, 2018, 20, e12894.	1.7	5
36	Chikungunya in a kidney transplant recipient: a case report. Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia, 2019, 41, 575-579.	0.9	5

#	Article	IF	CITATIONS
37	Oral manifestations of allograft recipients immediately before and after kidney transplantation. Acta Odontologica Scandinavica, 2020, 78, 217-222.	1.6	5
38	Migratory pattern of the coronavirus disease 2019 and high fatality rates among kidney transplant recipients: report from the Brazilian Multicenter Cohort Study. Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia, 2022, 44, 428-433.	0.9	5
39	Lower seroprevalence for SARSâ€CoVâ€2â€specific antibodies among kidney transplant recipients compared to the general population in the city of Sao Paulo, Brazil. Transplant Infectious Disease, 2021, 23, e13706.	1.7	5
40	Clinical features and outcomes of kidney transplant recipients with focal segmental glomerulosclerosis recurrence. Nephrology, 2019, 24, 1179-1188.	1.6	4
41	Strategies to keep kidney transplant alive amid the SARS-CoV-2 pandemic. Revista Da Associação Médica Brasileira, 2021, 67, 63-66.	0.7	4
42	The influence of the antithymocyte globulin dose on clinical outcomes of patients undergoing kidney retransplantation. PLoS ONE, 2021, 16, e0251384.	2.5	4
43	COVID-19 Among Kidney Transplant Recipients: A Look Into Latin America. Transplantation, 2022, 106, e185-e186.	1.0	4
44	The Mycophenolate-based Immunosuppressive Regimen Is Associated With Increased Mortality in Kidney Transplant Patients With COVID-19. Transplantation, 2022, 106, e441-e451.	1.0	4
45	Regional differences in the management and outcome of kidney transplantation in patients with human immunodeficiency virus infection: A 3â€year retrospective cohort study. Transplant Infectious Disease, 2017, 19, e12724.	1.7	3
46	Long-term Efficacy and Safety of Everolimus Versus Mycophenolate in Kidney Transplant Recipients Receiving Tacrolimus. Transplantation, 2021, Publish Ahead of Print, .	1.0	3
47	Clinical impact, reactogenicity, and immunogenicity after the first CoronaVac dose in dialysis patients: a phase IV prospective study. CKJ: Clinical Kidney Journal, 2021, 14, 2612-2615.	2.9	3
48	Prognosis of Patients with Primary Central Nervous System Post-Transplant Lymphoproliferative Disorder (PTLD-CNS) Treated with Immunossupression Reduction, Intrathecal Chemotherapy and Whole-Brain Radiotherapy: An Analysis of 23 Patients in a Brazilian Cohort. Blood, 2015, 126, 3913-3913.	1.4	3
49	De novo everolimus for recipients of kidney transplants from HLA identical donors. Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia, 2016, 38, 225-33.	0.9	2
50	Challenges of Multidrug-resistant New Delhi Metallo-beta-Lactamase (NDM-1)-producing Enterobacteriaceae in Kidney Transplant Patients. Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia, 2021, , .	0.9	2
51	Global Perspective on Kidney Transplantation: Brazil. Kidney360, 2021, 2, 2016-2018.	2.1	2
52	Aspergillus fumigatus as an agent of secondary cutaneous aspergillosis in a renal transplant recipient: a case report. International Journal of Dermatology, 2022, , .	1.0	2
53	Predictive ability of severity scores and outcomes for mortality in kidney transplant recipients with coronavirus disease 2019 admitted to the intensive care unit: results from a Brazilian single-center cohort study. Jornal Brasileiro De Nefrologia: Orgao Oficial De Sociedades Brasileira E Latino-Americana De Nefrologia, 2022, 44, 383-394.	0.9	2
54	Immunogenicity, reactogenicity and breakthrough infections after two doses of the inactivated CoronaVac vaccine among patients on dialysis: phase 4 study. CKJ: Clinical Kidney Journal, 2022, 15, 816-817.	2.9	2

#	Article	IF	CITATIONS
55	The Effect of Corticosteroid Withdrawal on Glucose Metabolism and Anti-GAD Antibodies in Simultaneous Pancreas–Kidney Transplant Patients. Progress in Transplantation, 2016, 26, 249-254.	0.7	1
56	Herpesviruses oral shedding and viremia in renal transplant recipients: A longitudinal study. Transplant Infectious Disease, 2020, 22, e13330.	1.7	1
57	Oral findings in kidney transplant children and adolescents. International Journal of Paediatric Dentistry, 2022, , .	1.8	1
58	Clinical Outcome of 96 Post-Transplant Lymphoproliferative Disease Patients in a Renal Transplant Cohort. Blood, 2015, 126, 5054-5054.	1.4	0
59	A Stentless Modified Lich-Gregoir Technique for Safe Early Bladder Catheter Removal in Living and Deceased Kidney Transplants. Urology, 2022, , .	1.0	0
60	Title is missing!. , 2020, 15, e0227445.		0
61	Title is missing!. , 2020, 15, e0227445.		O
62	Title is missing!. , 2020, 15, e0227445.		0
63	Title is missing!. , 2020, 15, e0227445.		0